Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease.

Date publication

octobre 2017

Journal

Clinical pharmacology and therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Hindryckx P, Novak G, Bonovas S, Peyrin-Biroulet L, Danese S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28699217

Résumé

The development of biologic drugs revolutionized the management of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. However, while their efficacy has been well established, it remains uncertain to what extent biologic treatments may be associated with important safety risks, such as serious infections, opportunistic infections, or tuberculosis reactivation. Herein, we review and discuss the current evidence on the infection risk associated with biologic therapy in patients with inflammatory bowel disease (IBD).

Mots clés

Biological Therapy, adverse effects, Humans, Immunologic Factors, adverse effects, Infection, epidemiology, Inflammatory Bowel Diseases, drug therapy, Opportunistic Infections, epidemiology, Tuberculosis, epidemiology

Référence

Clin. Pharmacol. Ther.. 2017 Oct;102(4):633-641